Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms

References

• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109-22
   PubMed Web of Science ®Google Scholar
• Okuyama H, Ichikawa Y, Sun Y-J, et al. Prevention of Coronary Heart Disease-from the cholesterol hypothesis to ω-6/ω-3 balance. Karger; Basel: 2007
   Google Scholar
• Ravnskov U. Fat and cholesterol are good for you!. GB Publishing; Sweden: 2009
   Google Scholar
• de Lorgeril M. Cholesterol and statins. Sham science and bad medicine. Thierry Souccar Publishing; Vergèze France: 2014
   Google Scholar
• Bollapragada SS, Norrie JD, Norman JE. Review of new regulations for the conduct of clinical trials of investigational medicinal products. BJOG 2007;114(18):917-21
   Google Scholar
• Okuyama H, Hamazaki T, Ogushi Y, et al. New Cholesterol Guidelines for Longevity (2010). World Rev Nutr Diet 2011;102:124-36
   PubMedGoogle Scholar
• Okuyama H, Hamazaki T, Ogushi Y, et al. Risks of diabetes mellitus and cancer caused by cholesterol lowering medications. Lipid Technology 2014;26(3):55-9; 10.1002/lite.201400010
   Google Scholar
• Mitchell P. Possible molecular mechanisms of the protonmotive function of cytochrome systems. J Theor Biol 1976;62(2):327-67
   Google Scholar
• Mitchell P. The classical mobile carrier function of lipophilic quinones in the osmochemistry of electron-driven proton translocation. In: Lenaz G, Barnabei O, Rabbi A, Battino M, editors. Highlights in Ubiquinone research. Taylor and Francis; London: 1990. p. 77-82
   Google Scholar
• Lenaz G, Fato R, Castellucio C, et al. Coenzyme Q saturation kinetics of mitochondrial enzymes: theory, experimental aspects and biomedical implications. In: Folkers K, Yamagami T, Littarru GP, editors. Biomedical and clinical aspects of coenzyme Q, (Vol 6). Elsevier; Amsterdam: 1991. p. 11-18
   Google Scholar
• Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660(1-2):171-99
   PubMed Web of Science ®Google Scholar
• Ernster L, Forsmark-Andrée P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 1993;71(8 Suppl):S60-5
   PubMedGoogle Scholar
• Villalba JM, Navarro F, Gómez-Díaz C, et al. Role of cytochrome b5 reductase on the antioxidant function of coenzyme Q in the plasma membrane. Mol Aspects Med 1997;18(Suppl):S7-13
   Google Scholar
• Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signaling. Mediators Inflamm 2010;2010:1-21
   Web of Science ®Google Scholar
• Hartenbach W. Die Cholesterin Lϋge-das Märchen vom bösen Cholesterin, F.A. Herbig Verlagsbuchhandlung GmbH; Mϋnchen: 2008
   Google Scholar
• Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013;61(1):44-53
   Google Scholar
• Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003;349(17):1605-13
   PubMed Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Inter Med 2012;172(2):144-52
   PubMed Web of Science ®Google Scholar
• Okuyama H, Hamazaki T, Ogushi Y, et al. Statins are contraindicant to diabetics-Urgent Proposal. J Lipid Nutr 2013;22(2):173-86; in Japanese with English summary
   Google Scholar
• Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998;18(9):1400-7
   PubMed Web of Science ®Google Scholar
• Booth SL, Lichtenstein AH, O’Brien-Morse M, et al. Effects of a hydrogenated form of vitamin K on bone formation and resorption. Am J Clin Nutr 2001;74(6):783-90
   Google Scholar
• Saremi A, Bahn G, Reaven PD, et al. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2012;35(11):2390-2
   PubMed Web of Science ®Google Scholar
• ADA: statin Use Tied to Faster Plaque Buildup. Published: Jun 11 2012. By Chris Kaiser, Cardiology Editor, MedPage Today Available from: http://www.medpagetoday.com/MeetingCoverage/ADA/33191
   Google Scholar
• Nakazato R, Gransar H, Berman DS, et al. Statins use and coronary artery plaque composition: results from the International Multicenter CONFIRM Registry. Atherosclerosis 2012;225(1):148-53
   PubMed Web of Science ®Google Scholar
• Schlieper G, Westenfeld R, Krüger T, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011;22(2):387-95
   PubMed Web of Science ®Google Scholar
• Matsuzaki M, Kita T, Mabuchi H, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002;66(12):1087-95
   Google Scholar
• Hamazaki T, Okuyama H, Ogushi Y, et al. Cholesterol issues in Japan - why are the goals of cholesterol levels set so low? Ann Nutr Metab 2013;62(1):32-6
   Google Scholar
• Thambidorai SK, Deshmukh AR, Walters RW, et al. Impact of statin use on heart failure mortality. Int J Cardiol 2011;147(3):438-43
   Google Scholar
• Kronmal RA, Cain KC, Ye Z, et al. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993;153(9):1065-73
   Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE, et al. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367(19):1792-802
   PubMed Web of Science ®Google Scholar
• Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007;81(5):650-3
   Google Scholar
• Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013;62(8):709-14
   PubMed Web of Science ®Google Scholar
• März W, Siekmeier R, Müller HM, et al. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther 2000;5(4):275-9
   Google Scholar
• Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995;116(2):1894-8
   Google Scholar
• Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 2000;35(2):256-62
   Google Scholar
• Ichihara K, Satoh K, Yamamoto A, et al. [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?]. Folia Pharmacol Jpn (Nihon Yakurigaku Zasshi) 1999;114(Suppl 1):142P-9P
   Google Scholar
• Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87(22):8931-4
   PubMed Web of Science ®Google Scholar
• Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004;94(10):1306-10
   Google Scholar
• Langsjoen PH, Langsjoen JO, Langsjoen AM, et al. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. BioFactors 2005;25(1-4):147-52
   Google Scholar
• Suzuki T, Nozawa T, Sobajima M, et al. Atorvastatin-induced changes in plasma coenzyme Q10 and brain natriuretic peptide in patients with coronary artery disease. Int Heart J 2008;49(4):423-33
   Google Scholar
• Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. BioFactors 2003;18(1-4):101-11
   PubMed Web of Science ®Google Scholar
• Fuhrmeister J, Tews M, Kromer A, et al. Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells. Toxicol Lett 2012;215(3):219-27
   Google Scholar
• Moosmann B, Behl C. Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends Cardiovasc Med 2004;14(7):273-81
   PubMed Web of Science ®Google Scholar
• Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004;363(9412):892-4
   PubMed Web of Science ®Google Scholar
• Keyhani J, Keyhani E. Mevalonic acid as a precursor of the alkyl sidechain of heme a of cytochrome c oxidase in yeast Saccharomyces cerevisiae. FEBS Lett 1978;93(2):271-4
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129(3):e28-292
   PubMed Web of Science ®Google Scholar
• Lefeber DJ, de Brouwer AP, Morava E, et al. Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet 2011;7(12):e1002427
   Google Scholar
• Kapusta L, Zucker N, Frenckel G, et al. From discrete dilated cardiomyopathy to successful cardiac transplantation in congenital disorders of glycosylation due to dolichol kinase deficiency (DK1-CDG). Heart Fail Rev 2013;18(2):187-96
   PubMed Web of Science ®Google Scholar
• Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97(12):1129-35
   PubMed Web of Science ®Google Scholar
• Huang KC, Chen CW, Chen JC, et al. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci 2003;10(4):396-405
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333(10):621-7
   PubMed Web of Science ®Google Scholar
• Bonsu KO, Kadirvelu A, Reidpath DD. Statins in heart failure: do we need another trial? Vasc Health Risk Manag 2013;9:303-19
   PubMedGoogle Scholar
• Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1231-9
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248-61
   PubMed Web of Science ®Google Scholar
• Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29(7):1478-85
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353(3):238-48
   PubMed Web of Science ®Google Scholar